Weiss Ratings reiterated their sell (d-) rating on shares of 908 Devices (NASDAQ:MASS - Free Report) in a research report released on Tuesday morning,Weiss Ratings reports.
Separately, Stephens reissued an "overweight" rating and issued a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $5.33.
Check Out Our Latest Stock Analysis on 908 Devices
908 Devices Price Performance
MASS stock traded up $0.42 during midday trading on Tuesday, hitting $4.21. 424,181 shares of the stock traded hands, compared to its average volume of 967,407. The stock's fifty day simple moving average is $3.38 and its 200-day simple moving average is $2.97. 908 Devices has a 1-year low of $1.81 and a 1-year high of $7.48. The firm has a market cap of $148.74 million, a P/E ratio of -2.38 and a beta of 0.30.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of MASS. Two Sigma Advisers LP purchased a new position in shares of 908 Devices during the fourth quarter worth about $30,000. Prudential Financial Inc. purchased a new position in 908 Devices during the 4th quarter worth approximately $34,000. Occudo Quantitative Strategies LP purchased a new position in 908 Devices during the 4th quarter worth approximately $36,000. Two Sigma Investments LP acquired a new position in 908 Devices during the fourth quarter worth approximately $42,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in 908 Devices in the third quarter valued at approximately $45,000. 88.06% of the stock is owned by hedge funds and other institutional investors.
908 Devices Company Profile
(
Get Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
